JP2024523422A5 - - Google Patents

Info

Publication number
JP2024523422A5
JP2024523422A5 JP2023578035A JP2023578035A JP2024523422A5 JP 2024523422 A5 JP2024523422 A5 JP 2024523422A5 JP 2023578035 A JP2023578035 A JP 2023578035A JP 2023578035 A JP2023578035 A JP 2023578035A JP 2024523422 A5 JP2024523422 A5 JP 2024523422A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
replaced
groups
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/099053 external-priority patent/WO2022262789A1/zh
Publication of JP2024523422A publication Critical patent/JP2024523422A/ja
Publication of JP2024523422A5 publication Critical patent/JP2024523422A5/ja
Pending legal-status Critical Current

Links

JP2023578035A 2021-06-17 2022-06-16 抗腫瘍化合物およびその応用 Pending JP2024523422A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110673571 2021-06-17
CN202110673571.1 2021-06-17
PCT/CN2022/099053 WO2022262789A1 (zh) 2021-06-17 2022-06-16 一种抗肿瘤化合物及其应用

Publications (2)

Publication Number Publication Date
JP2024523422A JP2024523422A (ja) 2024-06-28
JP2024523422A5 true JP2024523422A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=84526879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578035A Pending JP2024523422A (ja) 2021-06-17 2022-06-16 抗腫瘍化合物およびその応用

Country Status (11)

Country Link
US (1) US20240358848A1 (cg-RX-API-DMAC7.html)
EP (1) EP4357348A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523422A (cg-RX-API-DMAC7.html)
KR (1) KR20240022626A (cg-RX-API-DMAC7.html)
CN (1) CN119604509A (cg-RX-API-DMAC7.html)
AU (1) AU2022294861B2 (cg-RX-API-DMAC7.html)
CA (1) CA3223304A1 (cg-RX-API-DMAC7.html)
IL (1) IL309457A (cg-RX-API-DMAC7.html)
MX (1) MX2023015462A (cg-RX-API-DMAC7.html)
WO (1) WO2022262789A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202400544B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药(杭州)有限公司 适用于抗体-药物偶联物的毒素分子
CN119546344A (zh) * 2022-07-27 2025-02-28 明慧医药(杭州)有限公司 抗体药物偶联物及其应用
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药(杭州)有限公司 适用于抗体-药物偶联物的毒素分子
KR20250111373A (ko) 2022-11-25 2025-07-22 밍훼이 파마슈티컬 (항저우) 리미티드 항종양 화합물 및 이의 응용
WO2025241867A1 (zh) * 2024-05-24 2025-11-27 明慧医药(杭州)有限公司 抗b7-h4抗体药物偶联物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
ITMI20061473A1 (it) * 2006-07-26 2008-01-27 Indena Spa Derivati della camptotecina ad attivita antitumorale
US10195288B2 (en) * 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
CR20180229A (es) * 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
SG11201906554RA (en) * 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2020259258A1 (zh) * 2019-06-28 2020-12-30 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药(杭州)有限公司 适用于抗体-药物偶联物的毒素分子
AU2022269073A1 (en) * 2021-05-07 2023-11-23 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof

Similar Documents

Publication Publication Date Title
TWI871998B (zh) 抗her3抗體-藥物結合物
JP2022511351A5 (cg-RX-API-DMAC7.html)
JP2024081770A (ja) 抗her2抗体-薬物コンジュゲート
JP2012516896A5 (cg-RX-API-DMAC7.html)
JP2023519261A5 (cg-RX-API-DMAC7.html)
US20250320310A1 (en) A method for programmatically managing antibody disulfide bonds site-specific modification
JP2025508779A5 (cg-RX-API-DMAC7.html)
WO2024041543A1 (en) A method of preparing an antibody with thiol group site-specific modifications and use of tcep
US20260027227A1 (en) Novel thiol reductant, method and use thereof
WO2017194390A1 (en) Dimeric compounds
JP2024536798A5 (cg-RX-API-DMAC7.html)
WO2025261478A1 (en) Antibody drug conjugates and applications thereof
TH2101001650A (th) ลิแกนด์-ดรักคอนจูเกตของสารแอนะล็อกของเอกซาทีแคน, วิธีการเตรียมสำหรับคอนจูเกตนั้น และการประยุกต์ใช้คอนจูเกตดังกล่าว
RU2021110631A (ru) Конъюгат лиганд-лекарственное средство аналога экзатекана, способ его получения и его применение
HK40119434A (en) Camptothecin derivative and ligand-drug conjugate
RU2021110824A (ru) Конъюгат антитело к b7h3-аналог экзатекана и его применение в медицине
EA051826B1 (ru) Пептидные конъюгаты цитотоксинов в качестве терапевтических средств
TW202313125A (zh) 一種抗腫瘤化合物及其應用
NZ787254B2 (en) Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof